A 60-year-old man with type 2 diabetes and obesity asks about glucose-lowering agents for weight loss and CV benefit. Per ADA 2025, which class is rec...

Question

A 60-year-old man with type 2 diabetes and obesity asks about glucose-lowering agents for weight loss and CV benefit. Per ADA 2025, which class is recommended?

Accepted Answer

DPP-4 inhibitor

Answer

Sulfonylurea

Answer

GLP-1 receptor agonist with proven CV benefit

Answer

Basal insulin first

Answer

Acarbose

"endocrinology" MCQ (SBA): Type 2 Diabetes Mellitus

A 60-year-old man with type 2 diabetes and obesity asks about glucose-lowering agents for weight loss and CV benefit. Per ADA 2025, which class is recommended?